Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/98364
Authors: 
Lanjouw, Jean O.
Year of Publication: 
1997
Series/Report no.: 
Center Discussion Paper 775
Abstract: 
The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost fifty developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business interests in the West urged them to consider the beneficial effects such protection might bring both in terms of focusing more research on tropical diseases and encouraging greater domestic and foreign investment in local research activities. This paper discusses the various theoretical implications for a developing country of introducing product patents for pharmaceuticals. Using India as an example, it then brings together information gathered from both published sources and personal interviews to examine the potential magitude of these effects. While not arriving at a conclusive answer to the question posed in the title, there are some suggestions about the way events might unfold as the policy is implemented.
Document Type: 
Working Paper

Files in This Item:
File
Size
156.79 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.